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PRevention and tReatMent of Missing data in Real WoRld ReseaRch
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PurPose: The objective of this presentation is to bring awareness to the challenges of 
missing data from study design and analysis perspectives, and to discuss study design 
elements and analysis methods that support meaningful and valid inferences in both 
prospective and retrospective observational research used to generate real-world 
evidence for payers and health technology assessment authorities. DescriPtion: 
Observational studies are increasingly used to study the post approval drug exposed 
population for drug and medical effectiveness and safety assessments. Understanding 
the potential sources of missing data from a study whose design imposes structure on 
data captured from real world clinical practice allows the selection of study design ele-
ments that may help reduce the magnitude of missing data. Given the occurrence of 
missing data, analysis methods that support valid and meaningful conclusions from 
observational research are necessary. This presentation starts with an overview of the 
potential sources of missing data in observational research, including PRO assess-
ments and retrospective clinical data; then focuses on proactive planning of data 
collection and analysis. The types of missing data (missing due to study withdrawal; 
directly reported as missing; non-reported; uninterpretable value; out-of-range value) 
and statistical approaches for handling missing data including examining missing 
data patterns and testing missingness mechanisms, effective and advanced analytic 
methods (imputation, likelihood based and weighted approaches), when these meth-
ods should be applied, and the impact of missing data to the interpretation of study 
findings will be discussed. The concepts and methods will be explained with the use 
of real-world observational study data, including patient registries, electronic medical 
records, patient charts, and claims data.
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BAckgrounD: In face to the financial environment in which health facilities cur-
rently are evolving, it is now clear and shared that only through a good organization 
of the surgical event it is possible to achieve significant improvements in quality 
of care. In this way the economic impact becomes inversely proportional because 
the establish oneself of the virtuous circle that leads (or at least should lead) to 
a adequate request of resources that are used in a so much appropriate way to 
obtain the most practical benefit that ultimately produces case-mixes with high 
profitability, a good level of quality perceived as high and expenses pragmatically 
supported by the revenues. endpoints The primary endpoint of this study aims to 
assess, starting from the costs that the information analyzed allow to accurately 
calculate, the increased efficiency achieved by the availability to the anesthesiologist 
of sugammadex rather than its unavailability. Moreover, the secondary endpoint 
aims to formulate organizational scenarios to permit the unlimited use of sugam-
madex rather than have availability of it in a controlled amount for use based on a 
protocol. Furthermore, it tries to identify the surgical specialties in which each of 
the two scenarios can be applied with the highest profit. Methodology The Cost / 
Benefit Analysis (CBA) requires that the clinical indicators obtained be monetized 
by referring to cost and revenue. It is essential retrieve the information from the 
anesthesiology medical records (the prerequisite of validity for inclusion of the 
anesthesiology medical record is the presence of observation of the state of neu-
romuscular blockade by use of objective monitoring tools). Furthermore, it needs 
to retrieve the costs of the activity of the operating theatre from the management 
control system of the hospital. The revenues come from the clinical medical records.
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oBjectives: A recent cluster randomised controlled trial (RCT) conducted in an 
Irish hospital evaluating a structured pharmacist review of medication (SPRM) sup-
ported by computerised decision support software (CDSS) demonstrated positive 
outcomes in terms of reduction of adverse drug reactions (ADR). The aim of this 
study was to examine the cost-effectiveness of pharmacists applying a SPRM in 
conjunction with CDSS to older hospitalised patients compared to usual pharma-
ceutical care. MethoDs: Cost-effectiveness analysis alongside a cluster RCT. The 
trial was conducted in a tertiary hospital in the south of Ireland. The intervention 
arm patients (n= 361) received a multi-factorial intervention consisting of medicines 
reconciliation, deployment of CDSS and generation of pharmaceutical care plan for 
patient. Control arm patients (n= 376) received usual care from the hospital phar-
macy team. Incremental cost-effectiveness was examined in terms of costs to the 
healthcare system and an outcome measure of ADRs during an inpatient hospital 
stay. Uncertainty in the analysis was explored using a cost-effectiveness accept-
ability curve (CEAC). results: On average, the intervention arm was the dominant 
strategy in terms of cost-effectiveness. Compared to standard care (control), the 
intervention was associated with a decrease of € 815 (95% Confidence intervals (CI) 
-3451, 1820) (p = 0.544) in mean healthcare cost and a decrease in the mean number 
of ADR events per patient of -0.064 (95% CI -0.135, 0.008) (p = 0.081). The probability of 
the intervention being cost-effective at respective threshold values of € 0, € 250, € 500, 
for Tiotropium seen in blinded trials. Our examples demonstrate the useful applica-
tion of classical meta-analytic methods to assess heterogeneity across groups of 
trials based on aggregate data of relative treatment effect and its variability.
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oBjectives: This study aims to develop a theoretical scheme to achieve value-
based pricing in consideration of the efficiency with respect to the cost-effective-
ness dominance of a new technology, compared to the best control or the next best 
one. MethoDs: Suppose that a pair of cost and benefit of a new technology, the 
best control and next best one is respectively represented as three points with X(Ex, 
Cx), S(Es, Cs) and S’(Es’, Cs’) on the cost-effectiveness plane, assuming the inequali-
ties Es’ < Es < Ex and Cs’ < Cs < Cx. Let Cx be a variable, while the other parameters 
all constant. Considering geometric relations between the three points, we iden-
tify the areas where point X should be located according to the categories: simple 
dominance, extended dominance and non-dominance, in which we formulate the 
association between the expected cost Cx and the incremental cost-effectiveness 
ratio (ICER) of point X: (Cx - Cs)/(Ex - Es) compared to point S and (Cx - Cs’)/(Ex - Es’) 
to point S’. results: Three ranges for Cx were identified for each of the dominance 
categories, respectively, 1) lower than Cs’, 2 ) between Cs’ and Cm, and 3) greater 
than Cm, where Cm was estimated with the expression of ((Ex - Es’)Cs - (Ex - Es)Cs’)/
(Es - Es’). The expected cost Cx was formulated as a linear function of the ICER: Cx = 
Cs’ + (Ex - Es’)*ICERs’-x in case of dominance, whether simple or extended, and Cx = 
Cs + (Ex - Es)*ICERs-x for non-dominance. Based on the formulae, the maximal cost 
accepted in each category was determined in theory and with examples, taking an 
ICER threshold into account. conclusions: Our approach will provide decision 
makers with a scientific scheme for value-based pricing, and clarify the value position 
in consideration of economic efficiency.
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oBjectives: Due to specificities of medical devices (short lifetime, learning curve, 
limited approval process, steady technological development, etc.), it is desirable to 
take account of moral aging in HTA studies focused on devices. However, methods that 
might be used to evaluate innovations that are brought by a new generation of instru-
ments (and consider them in assessments of the older ones) are not well defined 
yet, although they are considered topical by many recent journal and conference 
papers. MethoDs: The paper consists of two parts. First, the history of innovations 
and their incorporation in HTA studies was studied for three typical devices (stents, 
MRI, left ventricular assist device – LVAD) with the focus on the delays in the particu-
lar analyses. Second, based on a literary review, a recommendation was formulated 
for assessment of devices in the case when innovations appear rapidly after each 
other. results: It is shown that older generations of devices are often being assessed 
when substantial innovations are already available, without taking them into con-
sideration. Classic CEA is probably difficult to apply. Two possible approaches were 
selected: MCDA applied on the effect side of the CEA (a modification of the method 
suggested by Rosina et al., Lékař a technika 44(3), 2014, 23-36), and the headroom 
method (Cosh et al., J Commer Biotechnol 13(4), 2007, 263-71). Their application is 
illustrated in the case of LVAD. CONCLUSION: The current methodologies for medi-
cal device assessment do not consider their moral ageing and/or innovations. The 
headroom method and/or MCDA may be a partial solution, as this paper suggests. 
Further more extensive studies are necessary in this direction.
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There are plenty of different clinical and economic parameters to consider in order 
to choose the best treatments. RCT and consequent Mixed Treatment Comparison 
(MTC) are based on the assessment of one single criterion, we need to move to a 
transparent and systematic framework enabling decision makers to assess all rel-
evant parameters simultaneously in order to evaluate the best intervention. In order 
to apply the Multiple Criteria Decision Analysis (MCDA) methodology to both clinical 
setting and decision making process we suggest the application of a model of MCDA 
as Clinical Multi-criteria Decision Assessment (CMDA). In this model of CMDA, we 
apply the methodology of MCDA in the context of a single disease, ie to compare 
biologicals in rheumatoid arthritis. Like for the general framework of MCDA, in 
CMDA there is not one predominant criterion; the innovative approach is to consider 
a “clinical consensus” for the selection of all relevant criteria (domains) and related 
parameters for evaluation, and the following attribution of specific weights. This 
means that clinical outcome measured on a specific endpoint (parameters) will 
be weighted according to the importance that a clinical consensus will give to the 
specific domain. This helps guaranty a transparent and objective evaluation. Results 
from both meta-analysis and observational studies are used by a clinical consensus 
after attributing weights to specific domains and related parameters. Decision will 
result from a related comparison of all parameters (i.e. efficacy, safety). The match 
will yield a score (in absolute value) that link each parameter with a specific inter-
vention, and then a final score for each treatment. The higher is the final score; the 
most appropriate is the intervention to treat disease considering all criteria (domain 
and parameters). The results will allow physicians evaluate best clinical treatment 
considering at the same time all relevant criteria.
